ERBB2 and breast cancer: A phase II trial presented at ASCO 2023 showed that albumin-bound paclitaxel combined with trastuzumab and pertuzumab, followed by anthracycline-based regimens, achieved a higher pCR in the HER2+/HR- BC subgroup (81·8%) compared to the HER2+/HR + subgroup (31·6%)93.